Literature DB >> 12640058

One year changes in disability in multiple sclerosis: neurological examination compared with patient self report.

E L J Hoogervorst1, M J Eikelenboom, B M J Uitdehaag, C H Polman.   

Abstract

OBJECTIVE: To characterise prospectively the relation between one year changes in neurologist rating of neurological exam abnormalities as measured by the Expanded Disability Status Scale (EDSS) and changes in patient perceived disability as measured by the Guy's Neurological Disability Scale (GNDS) in patients with multiple sclerosis.
METHODS: Two hundred and fifty patients with MS were recruited at an outpatient clinic. Disability at baseline and one year follow-up was assessed using the EDSS and GNDS. Correlations between change in EDSS, GNDS-sum score, Functional Systems and GNDS subcategories were studied as well as the significance of changes in EDSS associated with changes in perceived disability.
RESULTS: The correlation between one year changes in EDSS versus GNDS was substantially lower (0.19) than cross-sectional correlations between EDSS and GNDS either at baseline (0.62) or at follow-up (0.77). Notably, changes in functional system scores that are based on neurological examination are poorly or not at all correlated with changes in disability as perceived by the patient. Analysing the impact of a significant worsening in EDSS-score, a commonly applied outcome criterion in clinical trials, we found that this was associated with significant worsening, insignificant change, and significant improvement in the patients' perceived disability in 45%, 39% and 15% of patients, respectively.
CONCLUSION: Patients' perception of change in disability differs not only quantitatively but also qualitatively from that of an examining physician. This seems to be due both to the fact that there are true differences in change as perceived by the patient and that measured by the physician and to the fact that changes in many dimensions of disability that are relevant to the patient have no measurable impact on the EDSS.

Entities:  

Mesh:

Year:  2003        PMID: 12640058      PMCID: PMC1738360          DOI: 10.1136/jnnp.74.4.439

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  19 in total

1.  The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials.

Authors:  B G Weinshenker; G P Rice; J H Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1991-04       Impact factor: 13.501

2.  EDSS reliability.

Authors:  D E Goodkin
Journal:  Neurology       Date:  1991-02       Impact factor: 9.910

3.  Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.

Authors:  J N Whitaker; H F McFarland; P Rudge; S C Reingold
Journal:  Mult Scler       Date:  1995-04       Impact factor: 6.312

4.  Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis.

Authors:  E L Hoogervorst; N F Kalkers; B M Uitdehaag; C H Polman
Journal:  Mult Scler       Date:  2001-10       Impact factor: 6.312

5.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

6.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

7.  Reliability of distance estimation by doctors and patients: cross sectional study.

Authors:  B Sharrack; R A Hughes
Journal:  BMJ       Date:  1997 Dec 20-27

8.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

Review 9.  Clinical scoring methods for multiple sclerosis.

Authors:  J H Noseworthy
Journal:  Ann Neurol       Date:  1994       Impact factor: 10.422

10.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

View more
  12 in total

1.  Multiple sclerosis in the UK: service use, costs, quality of life and disability.

Authors:  Paul McCrone; Margaret Heslin; Martin Knapp; Paul Bull; Alan Thompson
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

2.  Telemedicine for Monitoring MS Activity and Progression.

Authors:  Nuria Sola-Valls; Yolanda Blanco; Maria Sepúlveda; Eugenia Martinez-Hernandez; Albert Saiz
Journal:  Curr Treat Options Neurol       Date:  2015-11       Impact factor: 3.598

3.  The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical).

Authors:  Lisa Costelloe; Killian O'Rourke; Hugh Kearney; Christopher McGuigan; Lisa Gribbin; Marguerite Duggan; Leslie Daly; Niall Tubridy; Michael Hutchinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-01       Impact factor: 10.154

4.  Oxygen cost of treadmill and over-ground walking in mildly disabled persons with multiple sclerosis.

Authors:  Robert W Motl; Yoojin Suh; Deirdre Dlugonski; Madeline Weikert; Stamatis Agiovlasitis; Bo Fernhall; Myla Goldman
Journal:  Neurol Sci       Date:  2010-08-27       Impact factor: 3.307

5.  The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure.

Authors:  C McGuigan; M Hutchinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-02       Impact factor: 10.154

6.  The MS Symptom and Impact Diary (MSSID): psychometric evaluation of a new instrument to measure the day to day impact of multiple sclerosis.

Authors:  J Greenhalgh; H Ford; A F Long; K Hurst
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-04       Impact factor: 10.154

7.  Development and validation of a new method to measure walking speed in free-living environments using the actibelt® platform.

Authors:  Michaela Schimpl; Christian Lederer; Martin Daumer
Journal:  PLoS One       Date:  2011-08-05       Impact factor: 3.240

8.  Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis.

Authors:  Z Khaleeli; J Sastre-Garriga; O Ciccarelli; D H Miller; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02-07       Impact factor: 10.154

9.  Cervical and thoracic cord atrophy in multiple sclerosis phenotypes: Quantification and correlation with clinical disability.

Authors:  Yair Mina; Shila Azodi; Tsemacha Dubuche; Frances Andrada; Ikesinachi Osuorah; Joan Ohayon; Irene Cortese; Tianxia Wu; Kory R Johnson; Daniel S Reich; Govind Nair; Steven Jacobson
Journal:  Neuroimage Clin       Date:  2021-04-28       Impact factor: 4.881

10.  The size of the treatment effect: do patients and proxies agree?

Authors:  Femke A H van der Linden; Jolijn J Kragt; Jeremy C Hobart; Martin Klein; Alan J Thompson; Henk M van der Ploeg; Chris H Polman; Bernard M J Uitdehaag
Journal:  BMC Neurol       Date:  2009-03-25       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.